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ABSTRACT
Hepatic angiosarcoma is a rare and aggressive vascular neoplasm. Pathogenic 
driver mutations are largely unknown. We present the case of a patient with recurrent 
hepatic angiosarcoma, who initially showed good response to sunitinib, followed 
by progression. Using comprehensive molecular techniques, we explored the 
potential mechanisms of resistance. By low-read-depth whole-genome sequencing, 
the comparison of copy number aberrations (CNAs) of the primary tumor to the 
skin metastatic lesion that developed after progression on sunitinib, revealed high-
level amplification of the 4q11-q13.1 region (containing KIT, PDGFRA and VEGFR2 
genes) that was sustained in both lesions. Whole exome sequencing on the germline, 
primary and metastatic tumor DNAs, resulted in 27 confirmed mutations, 19 of which 
(including TP53 mutation) presented in both primary and metastatic lesions. One 
mutation, ZNF331 frameshift deletion, was detected only in the primary tumor. In 
contrast, seven other mutations, including phospholipase C-gamma1 (PLCG1) R707Q 
mutation, were found only in the metastatic tumor, indicating selection of cells with 
the resistant genotype under sunitinib pressure. Our study supports the notion that 
PLCG1-R707Q mutation may confer VEGFR2-independent signaling and may thus 
cause resistance against VEGF(R)-directed therapies. This case illustrates also 
the advantages of using next-generation technologies in identifying individualized 
targeted therapy.
INTRODUCTION
Primary hepatic angiosarcoma is a rare soft 
tissue tumor, accounting for only 2% of all liver 
malignancies [1]. This vascular tumor originates from 
endothelial cells from blood or lymphatic vessels and 
has an aggressive behavior. Radical surgery with R0 
resection is the only curative treatment; however, the risk 
of recurrence remains high. Moreover, most patients are 
diagnosed with metastatic disease and this late diagnosis 
together with resistance against traditional chemo- and 
radiotherapy results in a poor outcome with a 2-year 
survival of only 3% of patients with metastatic disease [2]. 
Cytotoxic chemotherapy used for the treatment of 
metastatic disease includes anthracyclines, ifosfamide and 
taxanes, although there is only little evidence of activity in 
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angiosarcoma. In most centers, taxanes are the treatment 
of choice for hepatic angiosarcoma given its anti-
angiogenic properties [3, 4], even though retrospective 
analysis suggests that cutaneous angiosarcoma of the head 
and neck respond better to taxanes than angiosarcomas 
in other anatomical localizations, such as the liver [5]. 
Because angiosarcomas are malignant endothelial cell 
tumors, angiogenesis is believed to play an important 
role in its pathogenesis. Immunohistochemical analysis 
demonstrates overexpression of all the three subtypes 
of vascular endothelial growth factor receptors 
(VEGFR) [6], as well as  the VEGF regulators, HIF-1α 
and  β  [7].  In  about  10%  of  angiosarcomas,  mutations 
in the VEGFR2 or VEGFR3 can be detected [8, 9], and 
gene  expression  profiling  shows  upregulation  of TIE1, 
VEGFR2, SNRK, TEK (TIE2) and FLT1 (VEGFR1), all 
playing a role in angiogenesis. In contrast with other 
sarcomas, angiosarcomas show a low level of alterations 
in p53 (only 4% mutations) and PIK3CA/AKT/mTOR 
pathways [10]. A recent study analyzed 39 angiosarcomas 
by whole-genome, whole-exome and targeted sequencing 
and revealed recurrent mutations in PTPRB and PLCG1, 
both linked with angiogenesis [11]. Furthermore, 38% 
of tumors displayed at least one driver mutation in 
angiogenesis signaling genes. In addition, PLCG1-R707Q 
missense  mutation  has  been  confirmed  as  a  recurrent 
oncogenic event in angiosarcomas in another study [12].
Based on these molecular findings, several groups 
have explored the potential of anti-angiogenic agents such 
as the anti-VEGF monoclonal antibody bevacizumab, and 
the multi tyrosine kinase inhibitors sorafenib, sunitinib and 
pazopanib, with moderate results [13–16].
In this study, we present to our knowledge the first 
case of a hepatic angiosarcoma effectively treated with 
sunitinib. Moreover, we performed molecular analysis 
both pre- and post-treatment specimens of the tumor tissue 
to explore potential mechanisms of resistance.
RESULTS
Case presentation
A 56 year-old female was admitted in the 
emergency department with acute abdominal pain in 
the right hypochondriac region. Blood examination 
showed leukocytosis (17.33 × 109/L), anemia (11 g/dL), 
elevated alkaline phosphatases (669 U/L), gamma-
glutamyl  transferases  (117 U/L) and C-reactive protein 
(77 mg/dL).  Both  abdominal  ultrasound  and  computer 
tomography (CT) revealed a hypervascular large liver 
mass  in  segment  5,  6,  7  and  8,  with  active  bleeding 
(Figure 1A). An emergent celiac angiogram was 
conducted and showed contrast extravasation indicating 
an active tumor bleeding. Embolization was performed 
Figure 1: CT scans of primary tumor at diagnosis A. and the recurrent liver tumor at baseline B. and after 2 months 
treatment with sunitinib C. 
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after  super-selective  cannulation  until  flow  stasis. Two 
weeks later surgery was performed by laparoscopic right 
hemi-hepatectomy to remove the tumor. Both, frozen and 
formalin-fixed, paraffin embedded (FFPE) tissues from the 
resection specimen was available for molecular analysis.
Three months post-surgery, imaging by CT scan 
revealed a large local recurrence in the residual liver 
segment 4, as well as peritoneal implants, retroperitoneal 
lymph nodes and surrenal and lung metastases. A few days 
after the diagnosis of recurrence, the patient presented in the 
emergence department with an acute high gastro-intestinal 
bleeding, due to a duodenal metastasis of the angiosarcoma, 
for  which  she  first  received  endoscopic  treatment  and 
subsequently embolization. Thereafter, sunitinib was 
administered to the patient at a dose of 37.5 mg daily. No 
significant side effects occurred, including fatigue, hand-
food syndrome or gastrointestinal symptoms. Imaging 
after treatment with sunitinib for two months revealed a 
good response, with a decrease in tumor volume as well 
as a decrease in density (Figure 1B and 1C). After four 
months of treatment imaging by CT scan showed stable 
disease of the intra-abdominal lesions but progression of 
the lung metastases. Since the patient did not experience 
major side effects, the dose of sunitinib was increased to 50 
mg daily continuously. The patient developed hypertension 
for which an antihypertensive drug was prescribed. Two 
months after the sunitinib dose increase evaluation by CT 
scan revealed progressive disease of both the abdominal 
as the lung metastases. Moreover, patient developed skin 
metastases, from which a tumor biopsy was taken again 
for molecular analysis. Second line therapy was planned, 
however before the start of this treatment, the patient 
developed left hemiplegia with secondary hemorragia due 
to brain metastases, and she died shortly after.
Histopathology
Pathologic  examination  confirmed  an  infiltrative 
tumor composed of vascular channels delineated by 
atypical endothelial cells expressing the vascular 
markers CD31 and ERG, consistent with the diagnosis of 
angiosarcoma (Figure 2A and 2B). There was necrosis and 
mitotic figures were numerous. The tumor cells weakly 
expressed CD117 (Figure 2C).
Figure 2: Histopathology and immunoprofile of the primary tumor. A. Low power view, showing the transition from viable 
tumor to necrotic tumor. Note the presence of vascular channels. B. At high power the vascular channels are delineated by plump cells with 
atypical nuclei. Numerous mitoses are seen (arrows). Tumor cells are strongly positive for ERG C. and weakly for CD117 D.
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Cytogenetic and molecular analysis
The comparison of copy number aberrations 
(CNAs) of the primary tumor lesion to the skin metastatic 
lesion that developed after progression on sunitinib 
was performed by low-read-depth whole-genome 
sequencing using DNA isolated from FFPE tissues. After 
segmentation with ASCAT, both primary and metastatic 






which contains KIT, PDGFRA and VEGFR2. In the 
metastatic lesion, 4 high-level amplifications and 8 high-
level deletions were detected (Figure 3B, Supplementary 
Table S1). Although we also identified 8 regions that had 
a difference in copy number greater than 1.5 copies when 
comparing primary and metastatic tumor cell populations 
(Figure 3C, Supplementary Table S1), the amplification 
of the 4q11-q13.1 region was sustained in both lesions. 
Figure 3: Copy number aberrations detected by low-read-depth whole-genome sequencing in the primary A. and 
metastatic B. tumor lesions. Amplifications are shown in red, deletions in blue. Green dotted lines represent the thresholds for classification 
of the CNAs in 5 categories based on their copy number (CN), i.e. high-level deletions (CN < 1.5) and amplifications (CN > 4.5), low-level 
deletions (1.5 < CN < 2.5) and amplifications (3.5 < CN < 4.5) and copy-neutral regions (2.5 < CN < 3.5). Copy number changes between 
both lesions were determined by subtracting the copy number of the primary from the metastatic tumor lesion C. Loss of copies is indicated 
in blue, gain of copies in red. The green dotted line represents the threshold for differences in copy number by more than 1.5.
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Notably, high-level amplification of either C-MYC/8q24 
or FLT4/5q35 was not present in both lesions. A list of 
the 1435 genes occurring in the 19 regions with either 
high-level amplifications or deletions is available upon 
request.
Fluorescence In Situ Hybridization (FISH) was 
carried out for the validation of the genomic copy number 
changes and evaluation of tumor chromosome ploidy 
level (Supplementary Table S2). Generally, genomic 
copy number changes detected by low-read-depth whole-
genome sequencing were in line with results obtained by 
FISH. Of note, both lesions disclosed the presence of cells 
with the amplification of KIT, PDGFRA,VEGFR2/4q12 
genes in reference to chromosome 4 centromeric probe, 
albeit  significantly  lower  in  number  in  primary  versus 
metastatic lesion (33% vs. 81%, respectively) (Figure 4A 
and 4B), which was in good concordance with the tumor 
percentage of the biopsies by low-read-depth whole 
genome sequencing (17% vs. 48%, respectively).
Furthermore, we performed whole exome 
sequencing on the germline, primary tumor and 
metastatic tumor DNA, to determine somatic mutations. 
The detected mutations were validated using ultra-deep 
targeted resequencing, resulting in 27 confirmed mutations 
(Figure 5, Supplementary Table S3). Nineteen of those, 
including a mutation in TP53, were detected in both, 
primary and metastatic lesions. One mutation, namely a 
frameshift deletion in ZNF331 was detected only in the 
primary tumor. In contrast, seven other non-synonymous 
or frameshift mutations (in genes UGT3A2, PLCG1, 
OR10K1, COL9A1, MAGEA6, CNBD1 and LG14) 
were detected only in the metastatic tumor, indicating 
a selection and proliferative advantage of cells with the 
diverse genotype under sunitinib treatment.
Figure 4: Representative examples of dual-color interphase FISH images on paraffin sections. A. Primary liver angiosarcoma, 
showing amplification of PDGFRA and KIT genes (which maps at 4q12) in 33% of cells (arrows), as detected by the co-hybridization of 
SpectrumOrange labeled BAC’s PDGFRA/RP11–24O10 and KIT/RP11–959G16 DNA probes (red signals) and SpectrumGreen labeled 
chromosome 4 CEP probe (green signals). B. Skin metastases of relapsed tumor - using the same combination of probes, amplification of 
PDGFRA and KIT genes in reference to chromosome 4 CEP probe is detected in majority of cells (>80%).
Figure 5: Somatic mutations detected by whole-exome sequencing and validated using ultra-deep targeted 
resequencing. Primary-unique mutations are marked in blue and metastasis-unique mutations in green while mutations detected in both 
primary and metastasis are marked in orange.
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DISCUSSION
Angiosarcomas are generally resistant to 
chemotherapy and represent a tumor subset where novel 
therapeutic approaches are needed. In the patient described 
here, a good primary response had been seen after the 
administration of sunitinib, followed by the wide-spread 
metastatic refractory disease that developed six months 
later. Since underlying mechanisms of response and/
or resistance to targeted therapy in this deadly but rare 
disease were never investigated, we aimed to explore 
underlying genomic aberrations and viable treatment 
options. To this end we have compared CNAs and somatic 
mutations in the primary tumor and the skin metastatic 
lesion that developed after progression on sunitinib, using 
respectively low-read-depth whole-genome and whole-
exome sequencing.
Both, the primary and sunitinib-refractory tumor 
cells, harbored numerous and genome-wide distributed 
CNAs, with only partially overlapped regions of high-
level  gains/amplifications  and/or  losses.  Importantly, 
primary lesion disclosed the presence of cells sub-clone 
(~30%  of  cells)  with  the  amplification  of  the  4q12 
region, encompassing receptor kinase KIT, PDGFRA, 
and VEGFR2 genes. Recurrent gains of a small region 
of chromosome 4q12 containing KIT and VEGFR2 genes 
have been reported in sporadic angiosarcomas [12], and 
overexpression of vascular endothelial growth factors and 
their receptors have been linked with the good response 
of  these  tumors  to  sunitinib  [17].  Given  the  absence 
of activating missense mutations that confer sunitinib 
sensitivity,  the  amplification  of KIT, PDGFRA, and/or 
VEGFR2 may have represented the critical sunitinib target 
in our case and may explain the primary good response of 
the tumor to the drug. Nevertheless, the sub-clone with 
the  4q12  amplification  has  also  uniformly  dominated 
(~ 80% of cells) in the sunitinib-refractory metastatic 
lesion, indicating the selection of cells with the secondary 
molecular defect(s) accountable for sunitinib resistance. 
By whole-genome exome sequencing, 20 of non-
synonymous or frameshift gene mutations were detected 
in sunitinib-naïve, primary tumor; all but one (ZNF331 
frameshift deletion) were present also in sunitinib-
resistant, metastatic lesion. In contrast, seven mutations 
were found only in the metastatic tumor, including 
PLCG1-R707Q  missense  mutation.  Previous  reports 
have identified the latter as a recurrent somatic mutation 
in 9–30% of angiosarcomas [11, 12]. Further studies 
proved this mutation to cause constitutive activation of 
PLCG1 independently of receptor tyrosine kinases, and 
to enhance the aggressiveness of HUVEC endothelial 
cells in vitro by the increase of apoptosis resistance and 
upsurge of cells migration and invasiveness [12]. The 
PLCG1-R707Q mutation did not represent an initiating 
oncogenic event in our case. However, given the short 
time of the development of refractory disease, most likely 
this mutation pre-existed in some primary tumor cells 
and was selected as the aggressive metastatic sub-clone 
under the sunitinib pressure. This strongly supports the 
notion that the R707Q mutation impose the resistance to 
sunitinib, and thus might possibly cause resistance against 
other VEGF/VEGFR2-directed therapies. Alternatively, 
due to the high molecular genomic complexity of our 
case, the alternative mechanisms could play a role. The 
clinical usefulness of PLCG1 mutational status as a 
possible predictive biomarker in angiosarcomas in the 
context  of  vascular-specific  receptor  tyrosine  kinases 
directed therapies warrants further study. Finally, 
our approach illustrates the advantages of using next 




Histopathologic examination was performed on 
formalin  fixed  paraffin-embedded  (FFPE)  tissue.  Five-
micrometer sections were used for routine hematoxylin 
and eosin (H&E) and immunohistochemical stainings 
(avidin-biotin-peroxidase complex method), using the 
following antibodies: ERG (Abcam, monoclonal, clone 
EPR3864, prediluted), CD31 (DAKO, monoclonal, 
clone  JC70A,  prediluted),  CD117  (DAKO,  polyclonal, 
prediluted).
Copy number alteration (CNA) detection by low-
read-depth whole-genome sequencing
Shot-gun whole genome libraries were prepared 
using KAPA library preparation kit (KAPA Biosystems) 
according to the manufacturer’s instructions. After 
quantification  with  qPCR,  the  resulting  libraries  were 
sequenced on a HiSeq2000 (Illumina) at low coverage 
generating 21, 125, 380 50 bp reads on average. Raw 
sequencing reads were mapped to the human reference 
genome (NCBI37/hg19) using Burrows-Wheeler Aligner 
(BWA v0.5.8a). Picard (v1.43) was used to remove PCR 
duplicates. CNAs were  identified  by  binning  the  reads 
in 30Kb windows, correcting for genomic waves using 
the  PennCNV  software  package  [18]  and  the  resulting 
number of reads per 30 Kb window were transformed 
into log R-values. The ASCAT algorithm version 2.0.1 
[19] was used to segment the raw data and estimate tumor 
percentages and overall ploidy. Subsequently CNAs were 
classified in 5 categories based on their copy number (CN), 
i.e.  high-level  deletions  (CN <  1.5)  and  amplifications 




Fluorescence in situ hybridization (FISH)
For the validation of genomic copy number changes 
and evaluation of tumor chromosome ploidy level, either 
a commercially available centromere enumeration probes 
(CEP) or dual-color locus specific identifier (LSI) probes 
(all from Abbott Laboratories, Des Plaines, IL, USA), or 
the bacterial artificial chromosome (BAC) DNA probes 
differentially labeled with SpectrumGreen (SG) or 
SpectrumOrange (SO) (Abbott Molecular, Des Pllaines, 
IL, USA) were utilized for dual-color interphase FISH 
on the 5-μm paraffin tumor sections. The probes applied 
are listed in Supplementary Table S2. The BAC clones 
were selected based on their location in the UCSC Human 
Genome Browser Gateway (http://genome.ucsc.edu/ 
cgi-bin/hgGateway,GRCh37/hg19),  and  were  obtained 
from the BACPAC Resource Center (http://bacpac.chori.
org).  DNA  isolation,  probe  labeling  and  hybridization 
were performed as previously described [20]. For analysis, 
100 nuclei were scored manually for each set of probes 
in at least two different areas of the section using an 
Axioplan  2  (Jena,  Germany)  fluorescence  microscope, 
and  analyzed  with  CYTOVISION  software.  For  CEP 
probes,  from  0  to  1  signals  per  nucleus  in  >60%  of 
cells was defined as a whole chromosome loss. For LSI 
probes, the ratio of red to green signals was calculated. 




Shot-gun whole genome libraries were prepared 
using KAPA library preparation kit (KAPA Biosystems), 
according to the manufacturer’s instructions. Whole exome 
enrichment was performed using the SeqCapV3 exome 
enrichment kit (Roche), following the manufacturer’s 
instructions. Using the resulting whole-exome libraries 
2  ×  100  bp  paired  end  reads  were  generated  on  a 
HiSeq2000 using a V3 flowcell resulting in an average 
coverage of 51.5x.
Raw sequencing reads were mapped to the human 
reference genome (NCBI37/hg19) using Burrows-Wheeler 
Aligner  (BWA  v0.5.8a)  [21].  Picard  (v1.43)  was  used 
to remove PCR duplicates [22]. The Genome Analysis 
Tool Kit (GATK) was used for local realignment around 
insertions and deletions, base recalibration, and single 
nucleotide variant calling [23]. Insertions and deletions 
were called using Dindel [24]. Somatic mutations were 
identified  by  subtracting  variants  and  indels  detected 
in the matched germ-line DNA from those found in the 
tumor DNA. Low quality mutations were removed based 
on mapping quality and coverage and subsequently 
ANNOVAR  [25]  was  used  to  annotate  the  remaining 
mutations. Several databases were used to remove 
common  variants  (MAF  >  1%)  (dbSNP  version  132, 
1000 Genomes Project, Axiom Genotype Data Set and 
the Complete Genomics diversity panel (46 Hapmap 
individuals). For downstream analysis, exonic non-
synonymous mutations and frame shift indels were 
selected.
Ultra-deep targeted resequencing
Targeted sequencing primers for the detected 
mutations were designed using the MassARRAY Assay 
Design software. Universal sequence tags were added to 
the forward and reverse primers and the resulting oligos 
were used to generate amplicons (Roche FastStart High 
Fidelity PCR kit). In a second round of PCR, universal 
sequencing adapters containing a 10 base pair (bp) index 
were added to the target amplicons using Acces Array 
Barcode primers for Illumina Sequencing. Subsequently, 
the samples were denatured and sequenced on an Illumina 
MiSeq in a 2 × 75 bp paired end sequencing run using 




alleles were called using GATK and manually checked 
using IGV (average coverage 6393x)
Data accessibility
The whole-exome and low-read-depth whole-
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EGA under accession number EGAS00001001281.
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